In mass vaccination setting, vaccine is effective for symptomatic COVID-19, hospitalization, severe disease, death
Non-White Race Tied to Higher Likelihood of COVID-19 Infection
Age, not race, most important contributing factor for outcomes
AAN: Smell Loss Can Persist for Five Months After COVID-19
About half of those with compromised sense of smell during acute phase had not regained sense of smell at average of 150.1 days postdiagnosis
Symptoms ID’d That Should Trigger COVID-19 Testing
Testing people with any of seven key symptoms in the first three days of illness would detect 96 percent of symptomatic cases
FDA Warns Not to Rely on Pulse Oximetry for Diagnosis, Treatment Decisions
Safety communication follows NEJM study showing risk for inaccuracy with use of pulse oximeters in those with dark skin pigmentation
COVID-19 Vaccines Adapted to Fight Variants Will Not Require Long Clinical Trials: FDA
Most makers of approved COVID-19 vaccines have said they plan to adapt their vaccines to tackle variants
FDA: New Variants Mean COVID-19 Vaccines, Tests May Need Tweaking
Agency offers recommendations for companies seeking to modify already-approved vaccines, medicines, and tests so they can remain effective
Predictors of Death, Discharge ID’d for Diabetes Patients With COVID-19
Younger age, routine metformin therapy, and longer symptom duration on admission positively linked to discharge
Transplant Recipient Dies After Receiving COVID-19-Infected Lungs
Surgeon who handled the donor lungs also became infected and fell ill but recovered
SARS-CoV-2, COVID-19 Rates Decreased After One Vaccine Dose
Study among health care workers shows reductions in SARS-CoV-2 infection rates one to 14, 15 to 28 days after first dose of the BNT162b2 COVID-19 vaccine